Comparing Vapotherm (VAPO) and The Competition

Share on StockTwits

Vapotherm (NYSE: VAPO) is one of 119 public companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare Vapotherm to similar businesses based on the strength of its analyst recommendations, profitability, risk, institutional ownership, earnings, dividends and valuation.

Insider and Institutional Ownership

47.5% of Vapotherm shares are held by institutional investors. Comparatively, 50.8% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 16.0% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Vapotherm and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vapotherm N/A N/A N/A
Vapotherm Competitors -33.53% -43.32% -15.44%

Valuation & Earnings

This table compares Vapotherm and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Vapotherm $42.38 million N/A -1.45
Vapotherm Competitors $1.50 billion $148.34 million 46.16

Vapotherm’s rivals have higher revenue and earnings than Vapotherm. Vapotherm is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Vapotherm and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vapotherm 0 0 4 0 3.00
Vapotherm Competitors 771 2751 4935 249 2.54

Vapotherm currently has a consensus target price of $26.50, suggesting a potential upside of 32.50%. As a group, “Surgical & medical instruments” companies have a potential upside of 361.79%. Given Vapotherm’s rivals higher possible upside, analysts plainly believe Vapotherm has less favorable growth aspects than its rivals.

Summary

Vapotherm rivals beat Vapotherm on 6 of the 11 factors compared.

Vapotherm Company Profile

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit and Q50 compressor; and disposable products comprising single-use disposables and nasal interfaces. The company sells its products to hospitals through a direct sales force in the United States; and through distributors in various countries internationally. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Seaboard Corp  Sees Large Growth in Short Interest
Seaboard Corp Sees Large Growth in Short Interest
Zynga  Rating Lowered to Hold at BidaskClub
Zynga Rating Lowered to Hold at BidaskClub
Willdan Group  Stock Rating Upgraded by BidaskClub
Willdan Group Stock Rating Upgraded by BidaskClub
Zacks Investment Research Downgrades Royal Bank of Scotland Group  to Hold
Zacks Investment Research Downgrades Royal Bank of Scotland Group to Hold
Re/Max  Rating Lowered to Sell at Zacks Investment Research
Re/Max Rating Lowered to Sell at Zacks Investment Research
INTL Fcstone Inc  Short Interest Update
INTL Fcstone Inc Short Interest Update


© 2006-2019 Ticker Report